Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FER | P16591 | 1/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7336729 | 0.88 | CYP1A2 (0.55) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL9178423 | 0.81 | HTR2A (0.54) | CYP1A2SMN1; SMN2MAPTLMNA | |
| SCHEMBL9175873 | 0.81 | MAPT (0.58) | CYP1A2SMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL8204475 | 0.81 | CYP1A2 (0.42) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL477913 | 0.80 | CDK2 (0.56) | CYP1A2SMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL12396547 | 0.80 | ALOX5 (0.59) | CYP1A2SMN1; SMN2MEN1KMT2AALOX5 | |
| SCHEMBL11340676 | 0.79 | ALOX5 (0.46) | CYP1A2SMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL8188282 | 0.78 | ABL1 (0.50) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL13343869 | 0.78 | LMNA (0.41) | CYP1A2SMN1; SMN2ALDH1A1ALOX15MAPK10 | |
| SCHEMBL380110 | 0.78 | ALOX5 (0.61) | CYP1A2SMN1; SMN2ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA | 2025-04-24 | — | — | US | disclosed |
| US-20240390386-A1 | CDK8/19 INHIBITORS FOR PREVENTING DRUG RESISTANCE | UNIVERSITY OF SOUTH CAROLINA | 2024-11-28 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| WO-1999006403-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0804420-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5550122-A | INHIBIT REVERSE TRANSCRIPTASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1996022282-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0415303-B1 | Pyrido [2,3-b][1,5]benzoxazepin (and thiazepin)-5(6H)-ones and -thiones and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMA (US) | 1995-12-13 | — | — | EP | disclosed |
| EP-0607129-B1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE | THERABEL RESEARCH SA (BE) | 1995-08-23 | — | — | EP | disclosed |
| US-5393752-A | Psycholigical disorders | THERABEL RESEARCH S.A./N.V. (BE) | 1995-02-28 | — | — | US | disclosed |
| EP-0607129-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE. | THERABEL RESEARCH SA (BE) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993007143-A1 | METHYLPIPERAZINOAZEPINE DERIVATIVES, THEIR PREPARATION AND USE | THERABEL RESEARCH S.A./N.V. (BE) | 1993-04-15 | — | — | WO | disclosed |
| EP-0415303-A2 | Pyrido [2,3-b][1,5]benzoxazepin (and thiazepin)-5(6H)-ones and -thiones and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | CDK8, CDK9, CDK18 | CYP1A2 4043/4885SMN1; SMN2 2604/4885ALDH1A1 4593/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | CYP1A2 3844/4885SMN1; SMN2 1482/4885ALDH1A1 1086/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | CYP1A2 1799/4885SMN1; SMN2 3594/4885ALDH1A1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.